Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00090298|
Recruitment Status : Completed
First Posted : August 30, 2004
Last Update Posted : March 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hypercholesterolemia||Drug: MK0653A, ezetimibe (+) simvastatin Drug: Comparator: Rosuvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2815 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia|
|Study Start Date :||April 2004|
|Actual Primary Completion Date :||December 2004|
|Actual Study Completion Date :||December 2004|
- LDL-C lowering efficacy after 6 weeks.
- Safety;changes in TC, non-HDL-C, TG, HDL-C, Apo B, LDL-C/HCL-C ratio.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00090298
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|